Paul Grint's most recent trade in Inhibikase Therapeutics Inc was a trade of 30,000 Stock Option (right to buy) done . Disclosure was reported to the exchange on July 16, 2024.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Inhibikase Therapeutics Inc | Paul C. Grint | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jul 2024 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Inhibikase Therapeutics Inc | Paul C. Grint | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2023 | 6,667 | 6,667 | - | - | Stock Option (right to buy) | |
| Inhibikase Therapeutics Inc | Paul C. Grint | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2022 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| Inhibikase Therapeutics Inc | Paul C. Grint | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2021 | 22,677 | 22,677 | - | - | Stock Option (right to buy) | |
| Inhibikase Therapeutics Inc | Paul C. Grint | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Dec 2020 | 6,825 | 6,825 | - | - | Stock Option (right to buy) |